{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:27Z","timestamp":1793042127178,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117189","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:42:29Z","timestamp":1786786949000},"page":"117189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pre-treatment T cell phospho-signalling identifies clinical pembrolizumab response in non-small cell lung cancer patients"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1018-9622","authenticated-orcid":false,"given":"J.D.J.","family":"Verdonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"R.","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van Rijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-2153","authenticated-orcid":false,"given":"M.M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-7502","authenticated-orcid":false,"given":"H.J.P.M.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-1058","authenticated-orcid":false,"given":"R.L.","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1634\/theoncologist.2016-0189","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer","volume":"22","author":"Herzberg","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2026.117189_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.lungcan.2017.11.012","article-title":"Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: data from the expanded access program and routine clinical care in a tertiary cancer centre-the Netherlands cancer institute","volume":"126","author":"Schouten","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117189_bb0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14737159.2017.1393333","article-title":"Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system","volume":"17","author":"Grizzi","year":"2017","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.intimp.2026.117189_bb0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/his.14040","article-title":"Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review","volume":"76","author":"Koomen","year":"2020","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.intimp.2026.117189_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117189_bb0030","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.intimp.2026.117189_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2026.117189_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112626","article-title":"Emerging blood-based biomarkers for predicting immunotherapy response in NSCLC","volume":"14","author":"Oitab\u00e9n","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117189_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114754","article-title":"Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality","volume":"157","author":"Verdonk","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117189_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117189_bb0055","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2026.117189_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cyto.a.24927","article-title":"OMIP-112: 42-parameter (40-color) spectral flow cytometry panel for comprehensive immunophenotyping of human peripheral blood leukocytes","volume":"107","author":"Waaijer","year":"2025","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0065","doi-asserted-by":"crossref","first-page":"2156317","DOI":"10.1080\/19420862.2022.2156317","article-title":"Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study","volume":"15","author":"Shchelokov","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0070","doi-asserted-by":"crossref","first-page":"17252","DOI":"10.1038\/s41598-019-53463-0","article-title":"Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells","volume":"9","author":"Bardhan","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2026.117189_bb0075","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.4049\/jimmunol.1301587","article-title":"Focal adhesion kinase negatively regulates Lck function downstream of the T cell antigen receptor","volume":"191","author":"Chapman","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-065X.2008.00745.x","article-title":"T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance","volume":"228","author":"Salmond","year":"2009","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2026.117189_bb0085","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a002279","article-title":"ZAP-70: an essential kinase in T-cell signaling","volume":"2","author":"Wang","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12979-025-00526-8","article-title":"P38 mitogen-activated protein kinase drives senescence in CD4(+) T lymphocytes and increases their pathological potential","volume":"22","author":"Gonz\u00e1lez-Osuna","year":"2025","journal-title":"Immun. Ageing"},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ph13010009","article-title":"Mitogen-activated protein kinase inhibitors and T-cell-dependent immunotherapy in cancer","volume":"13","author":"Kumar","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2567.2010.03345.x","article-title":"Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor","volume":"132","author":"Li","year":"2011","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.intimp.2026.117189_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT Signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117189_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117189_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J. Immunother."},{"issue":"19","key":"10.1016\/j.intimp.2026.117189_bb0120","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid Tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117189_bb0125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00280-022-04414-6","article-title":"First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers","volume":"89","author":"Felip","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117189_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.117189_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114215","article-title":"AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers","volume":"149","author":"Zhou","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117189_bb0140","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117189_bb0145","article-title":"Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants","volume":"6","author":"Revach","year":"2025","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.intimp.2026.117189_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1285798","article-title":"Cytotoxic CD8(+) Temra cells show loss of chromatin accessibility at genes associated with T cell activation","volume":"15","author":"T\u00fcrk","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117189_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-7-310","article-title":"PD-1 expression on peripheral CD8+ TEM\/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients","volume":"7","author":"Shen","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2026.117189_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.117189_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001607","article-title":"Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer","volume":"8","author":"Hurkmans","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117189_bb0170","article-title":"Directing T-cell immune responses for cancer vaccination and immunotherapy","volume":"9","author":"Smith","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"6","key":"10.1016\/j.intimp.2026.117189_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/imcb.12636","article-title":"T-cell activation-induced marker assays in health and disease","volume":"101","author":"Poloni","year":"2023","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2026.117189_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108399","article-title":"The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases","volume":"245","author":"Retnakumar","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.117189_bb0185","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfma.2025.04.023","article-title":"Regulation of T cell receptor (TCR) signaling by tyrosine phosphatases: recent advances and implication for therapeutic approach in autoimmune diseases","volume":"125","author":"Wu","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.intimp.2026.117189_bb0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2026.117189_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2026.117189_bb0200","article-title":"The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:44:40Z","timestamp":1790437480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S1567576926010350"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117189","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-treatment T cell phospho-signalling identifies clinical pembrolizumab response in non-small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117189"}}